Bergen, Norway, 23 April 2021; The Board of Directors in BerGenBio ASA (the
"Company") (OSE: BGBIO) have, to fulfil the Company's obligations under the
share option agreements and in accordance with the authorization granted by the
general meeting on 19 March 2021, resolved to increase the Company's share
capital by NOK 6,617.30 by issuance of 66,173 new shares. The new shares are
subscribed for by option owners who wishes and are entitled to exercise options
in accordance with the Company's option scheme. Each option gives a right to
receive one share in the Company. The subscription price is in accordance with
the prevailing options price pursuant to the Company´s option scheme, in average
NOK 17.46 per share.
The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,788,775.50 consisting of 87,887,755 shares, each with a par value of
NOK 0.10.
-End-
Contacts
Richard Godfrey CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.